Janchor Partners
VC Fund
Central, Hong Kong
Janchor Partners is a VC fund in Central focused on Health Care and Pharmaceutical. Established in 2009, Janchor Partners is a long‐term industrialist investor, partnering with companies that have superior business models, favorable growth prospects and the potential to be part of long‐term positive structural dynamics of Asian countries and economies. As a genuine thought partner with its investee companies, Janchor Partnershelps to increase long‐term corporate value and builds strong long‐term relationships with investee companies.Janchor Partners’ mission as an Industrialist Investor is anchored by its purpose to have a lasting impact through deep relationships by building insight and trust. This virtuous cycle of impact, insight and trust can produce win-win-win holistic outcomes that create long-term sustained value.Janchor Partners’ ability to invest for the long‐term is strengthened by its investment partners, comprising high quality global institutional investors including family offices, university endowments, foundations and pension funds, who commit their capital to Janchor Partners for multi‐year periods.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Janchor Partners invests in
Stages Janchor Partners invests in
Countries Janchor Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Ho
|
|||
Investment Focus
Industry
- Health Care 5 (42%)
- Pharmaceutical 5 (42%)
- Biotechnology 4 (33%)
- FinTech 2 (17%)
- Medical 2 (17%)
Stage
- Series A 4 (33%)
- Series C 4 (33%)
- Series D 2 (17%)
- Funding Round 1 (8%)
- Private Equity 1 (8%)
Country
- China 6 (50%)
- India 1 (8%)
- Australia 1 (8%)
- Singapore 1 (8%)
- United States 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
John Ho
Founder
|
Founder | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kody
|
Founded by a small group of final-year high school students and launched in 2023, Founder Yoyo Chang (CEO) studied at the University of Cambridge & York whilst raising over US$40M. Today, Kody's AI-native financial infrastructure and Agentic Commerce platform is growing to connect millions of users to leading businesses all over the world. | $27M / Series A / Nov 16, 2024 | |
Eden Brew
|
Eden Brew is a food and beverage company providing a range of animal-free and precision-fermented milk and dairy products. | $15.4M / Series A / Oct 03, 2023 | |
FPL Technologies
|
FPL believes that consumption credit presents a very large opportunity in India and the credit card is the best product to offer consumption credit to India’s growing younger population. Card acceptance has trebled in the three years after demonetisation and every category is getting digitized. Like the overall growth in adoption of digitalpayments, the adoption of credit cards too has grown, both in terms of card issuance and spends. However, the experience of using a credit card has not evolved to serve the digitally savvy young millennials.FPL has created a proprietary full-stack technology platform to deliver a next-gen credit card experience to its customers. Customers can use an intuitive mobile app along with their credit cards to manage every aspect of their credit life cycle. FPL launched the OneScore app in July this year to help customers understand and manage their credit score and behavior in a simple and secure way. | $75M / Series C / Dec 30, 2021 | |
Carro
|
Carro is an online used car marketplace that offers a wide range of services for buying a car. | $100M / Series C / Nov 30, 2021 | |
MediTrust Health
|
MediTrust Health is a leading medical innovation payment service brand in China. | $308M / Series C / Aug 10, 2021 | |
Abbisko Therapeutics
|
Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China. | $123M / Series D / Jan 07, 2021 | |
InventisBio
|
InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas. | $147M / Series D / Sep 27, 2020 | |
Everest Medicines
|
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in the Emerging Market including Asia Pacific territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients inthe Emerging Market and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in Asia Pacific territories and with leading global pharmaceutical companies. | $310M / Series C / Jun 03, 2020 | |
Remegen
|
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates(ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California. | $100M / Mar 17, 2020 | |
|
Remegen
|
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates(ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California. | $100M / Private Equity / Mar 17, 2020 | |
| See all 12 investments → | |||
Co-Investors
Lilly Asia Ventures
6 deals together
Lake Bleu Capital
5 deals together
OrbiMed
5 deals together
Hudson Bay Capital Management
3 deals together
Vivo Capital
3 deals together
Advantech Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Janchor Partners invest in?
Janchor Partners invests primarily in Health Care, Pharmaceutical and Biotechnology startups, most often at Series A and Series C stage. Most of the 12 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Janchor Partners?
Public channels for Janchor Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Janchor Partners?
The team at Janchor Partners includes John Ho (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
